Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KCNJ1 | P48048 | 4/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.48 |
| ▸ | PARP1 | P09874 | 7/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | APAF1 | O14727 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6483093 | 0.85 | PARP1 (0.48) | HRH3KCNJ1KCNH2PARP1 | |
| SCHEMBL6483613 | 0.82 | PARP1 (0.47) | PARP1MAPTKMT2A | |
| SCHEMBL5653299 | 0.70 | HRH3 (0.93) | HRH3KCNJ1KCNH2SIGMAR1MAOA | |
| SCHEMBL3156895 | 0.70 | HRH3 (1.00) | HRH3KCNJ1KCNH2SIGMAR1MAOA | |
| SCHEMBL6483005 | 0.69 | PTGDR2 (0.51) | SMN1; SMN2PARP1MEN1MAPTKMT2A | |
| SCHEMBL3156570 | 0.68 | HRH3 (0.97) | HRH3KCNJ1KCNH2SIGMAR1MAOA | |
| SCHEMBL914324 | 0.68 | HRH3 (0.97) | HRH3KCNJ1KCNH2SIGMAR1MAOA | |
| SCHEMBL25792230 | 0.68 | KCNJ1 (0.48) | HRH3KCNJ1KCNH2MEN1KMT2A | |
| SCHEMBL6494377 | 0.68 | PARP1 (0.61) | PARP1 | |
| SCHEMBL6481336 | 0.68 | PARP1 (0.49) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050159431-A1 | Substituted alkyl uracils and thereof | BAYER HEALTHCARE AG (DE) | 2005-07-21 | — | — | US | disclosed |
| EP-1467975-A1 | SUBSTITUTED ALKYL URACILS AND THE USE THEREOF | Bayer HealthCare AG (DE) | 2004-10-20 | — | — | EP | disclosed |
| WO-2003059892-A1 | SUBSTITUTED ALKYL URACILS AND THE USE THEREOF | BAYER HEALTHCARE AG (DE) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159431-A1 | Substituted alkyl uracils and thereof | UNG, UMPS, TYMP | HRH3 2268/4885SMN1; SMN2 1144/4885KCNJ1 3513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.